287 related articles for article (PubMed ID: 27980108)
61. Enhancement of pomalidomide anti-tumor response with ACY-241, a selective HDAC6 inhibitor.
North BJ; Almeciga-Pinto I; Tamang D; Yang M; Jones SS; Quayle SN
PLoS One; 2017; 12(3):e0173507. PubMed ID: 28264055
[TBL] [Abstract][Full Text] [Related]
62. Repressing MYC by targeting BET synergizes with selective inhibition of PI3Kα against B cell lymphoma.
Chen ZQ; Cao ZR; Wang Y; Zhang X; Xu L; Wang YX; Chen Y; Yang CH; Ding J; Meng LH
Cancer Lett; 2022 Jan; 524():206-218. PubMed ID: 34688842
[TBL] [Abstract][Full Text] [Related]
63. Design, synthesis and anticancer potential of NSC-319745 hydroxamic acid derivatives as DNMT and HDAC inhibitors.
Yuan Z; Sun Q; Li D; Miao S; Chen S; Song L; Gao C; Chen Y; Tan C; Jiang Y
Eur J Med Chem; 2017 Jul; 134():281-292. PubMed ID: 28419930
[TBL] [Abstract][Full Text] [Related]
64. The Bromodomain Inhibitor JQ1 and the Histone Deacetylase Inhibitor Panobinostat Synergistically Reduce N-Myc Expression and Induce Anticancer Effects.
Shahbazi J; Liu PY; Atmadibrata B; Bradner JE; Marshall GM; Lock RB; Liu T
Clin Cancer Res; 2016 May; 22(10):2534-44. PubMed ID: 26733615
[TBL] [Abstract][Full Text] [Related]
65. CUDC-101, a multitargeted inhibitor of histone deacetylase, epidermal growth factor receptor, and human epidermal growth factor receptor 2, exerts potent anticancer activity.
Lai CJ; Bao R; Tao X; Wang J; Atoyan R; Qu H; Wang DG; Yin L; Samson M; Forrester J; Zifcak B; Xu GX; DellaRocca S; Zhai HX; Cai X; Munger WE; Keegan M; Pepicelli CV; Qian C
Cancer Res; 2010 May; 70(9):3647-56. PubMed ID: 20388807
[TBL] [Abstract][Full Text] [Related]
66. Chidamide, a histone deacetylase inhibitor, functions as a tumor inhibitor by modulating the ratio of Bax/Bcl-2 and P21 in pancreatic cancer.
Zhao B; He T
Oncol Rep; 2015 Jan; 33(1):304-10. PubMed ID: 25384499
[TBL] [Abstract][Full Text] [Related]
67. Entinostat, a novel histone deacetylase inhibitor is active in B-cell lymphoma and enhances the anti-tumour activity of rituximab and chemotherapy agents.
Frys S; Simons Z; Hu Q; Barth MJ; Gu JJ; Mavis C; Skitzki J; Song L; Czuczman MS; Hernandez-Ilizaliturri FJ
Br J Haematol; 2015 May; 169(4):506-19. PubMed ID: 25712263
[TBL] [Abstract][Full Text] [Related]
68. Parsaclisib Is a Next-Generation Phosphoinositide 3-Kinase
Shin N; Stubbs M; Koblish H; Yue EW; Soloviev M; Douty B; Wang KH; Wang Q; Gao M; Feldman P; Yang G; Hall L; Hansbury M; O'Connor S; Leffet L; Collins R; Katiyar K; He X; Waeltz P; Collier P; Lu J; Li YL; Li Y; Liu PCC; Burn T; Covington M; Diamond S; Shuey D; Roberts A; Yeleswaram S; Hollis G; Metcalf B; Yao W; Huber R; Combs A; Newton R; Scherle P
J Pharmacol Exp Ther; 2020 Jul; 374(1):211-222. PubMed ID: 32345620
[TBL] [Abstract][Full Text] [Related]
69. A histone deacetylase inhibitor enhances expression of genes inhibiting Wnt pathway and augments activity of DNA demethylation reagent against nonsmall-cell lung cancer.
Shieh JM; Tang YA; Hu FH; Huang WJ; Wang YJ; Jen J; Liao SY; Lu YH; Yeh YL; Wang TW; Lin P; Wang YC
Int J Cancer; 2017 May; 140(10):2375-2386. PubMed ID: 28233309
[TBL] [Abstract][Full Text] [Related]
70. Suppression of BCL6 function by HDAC inhibitor mediated acetylation and chromatin modification enhances BET inhibitor effects in B-cell lymphoma cells.
Cortiguera MG; García-Gaipo L; Wagner SD; León J; Batlle-López A; Delgado MD
Sci Rep; 2019 Nov; 9(1):16495. PubMed ID: 31712669
[TBL] [Abstract][Full Text] [Related]
71. Human ATP-Binding Cassette transporters ABCB1 and ABCG2 confer resistance to CUDC-101, a multi-acting inhibitor of histone deacetylase, epidermal growth factor receptor and human epidermal growth factor receptor 2.
Wu CP; Hsiao SH; Su CY; Luo SY; Li YQ; Huang YH; Hsieh CH; Huang CW
Biochem Pharmacol; 2014 Dec; 92(4):567-76. PubMed ID: 25450670
[TBL] [Abstract][Full Text] [Related]
72. Inhibition of MEK suppresses hepatocellular carcinoma growth through independent MYC and BIM regulation.
Zhou X; Zhu A; Gu X; Xie G
Cell Oncol (Dordr); 2019 Jun; 42(3):369-380. PubMed ID: 30788663
[TBL] [Abstract][Full Text] [Related]
73. Targeting Phosphatidylinositol 3-Kinase Signaling Pathway for Therapeutic Enhancement of Vascular-Targeted Photodynamic Therapy.
Kraus D; Palasuberniam P; Chen B
Mol Cancer Ther; 2017 Nov; 16(11):2422-2431. PubMed ID: 28835385
[TBL] [Abstract][Full Text] [Related]
74. Characterization of LY3023414, a Novel PI3K/mTOR Dual Inhibitor Eliciting Transient Target Modulation to Impede Tumor Growth.
Smith MC; Mader MM; Cook JA; Iversen P; Ajamie R; Perkins E; Bloem L; Yip YY; Barda DA; Waid PP; Zeckner DJ; Young DA; Sanchez-Felix M; Donoho GP; Wacheck V
Mol Cancer Ther; 2016 Oct; 15(10):2344-2356. PubMed ID: 27439478
[TBL] [Abstract][Full Text] [Related]
75. JQ1 suppresses tumor growth via PTEN/PI3K/AKT pathway in endometrial cancer.
Qiu H; Li J; Clark LH; Jackson AL; Zhang L; Guo H; Kilgore JE; Gehrig PA; Zhou C; Bae-Jump VL
Oncotarget; 2016 Oct; 7(41):66809-66821. PubMed ID: 27572308
[TBL] [Abstract][Full Text] [Related]
76. Cutaneous T-Cell Lymphoma PDX Drug Screening Platform Identifies Cooperation between Inhibitions of PI3Kα/δ and HDAC.
Wu CH; Yang CY; Wang L; Gao HX; Rakhshandehroo T; Afghani S; Pincus L; Balassanian R; Rubenstein J; Gill R; Bandyopadhyay S; McCormick F; Moasser M; Ai WZ
J Invest Dermatol; 2021 Feb; 141(2):364-373. PubMed ID: 32603749
[TBL] [Abstract][Full Text] [Related]
77. Dual targeting of GSK3B and HDACs reduces tumor growth and improves survival in an ovarian cancer mouse model.
Taylan E; Zayou F; Murali R; Karlan BY; Pandol SJ; Edderkaoui M; Orsulic S
Gynecol Oncol; 2020 Oct; 159(1):277-284. PubMed ID: 32698955
[TBL] [Abstract][Full Text] [Related]
78. BET Inhibition Induces Apoptosis in Aggressive B-Cell Lymphoma via Epigenetic Regulation of BCL-2 Family Members.
Hogg SJ; Newbold A; Vervoort SJ; Cluse LA; Martin BP; Gregory GP; Lefebure M; Vidacs E; Tothill RW; Bradner JE; Shortt J; Johnstone RW
Mol Cancer Ther; 2016 Sep; 15(9):2030-41. PubMed ID: 27406984
[TBL] [Abstract][Full Text] [Related]
79. Histone deacetylase inhibitor romidepsin induces efficient tumor cell lysis via selective down-regulation of LMP1 and c-myc expression in EBV-positive diffuse large B-cell lymphoma.
Shin DY; Kim A; Kang HJ; Park S; Kim DW; Lee SS
Cancer Lett; 2015 Aug; 364(2):89-97. PubMed ID: 25790907
[TBL] [Abstract][Full Text] [Related]
80. p21 Downregulation is an important component of PAX3/FKHR oncogenicity and its reactivation by HDAC inhibitors enhances combination treatment.
Hecker RM; Amstutz RA; Wachtel M; Walter D; Niggli FK; Schäfer BW
Oncogene; 2010 Jul; 29(27):3942-52. PubMed ID: 20453878
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
